AstraZeneca Uses AI Llamas to Market Breztri's Asthma Expansion
The pharmaceutical giant is leveraging AI-driven humor and a scientific pun to reach a younger patient demographic.
AstraZeneca has launched a high-concept advertising campaign for its Breztri inhaler to mark the drug's entry into the asthma maintenance market. The initiative replaces traditional pharmaceutical imagery with AI-generated animals to simplify complex medical terminology for patients.
Developed by the agency Edelman, the campaign features AI-generated llamas, goats, and oryx acting as office co-workers in what the creators describe as a "wonderfully weird" environment. The use of llamas is a deliberate pun on LAMA, which stands for Long Acting Muscarinic Antagonist, one of the active components in Breztri’s triple-combination therapy. These ads are being distributed across a digital-first ecosystem, including connected TV, YouTube, social media, and various display networks.
Strategic Market Expansion
Breztri Aerosphere was previously approved and marketed exclusively for the maintenance of chronic obstructive pulmonary disease (COPD). The shift toward asthma maintenance follows the completion of several Phase 3 trials, specifically the KALOS, LOGOS, LITHOS, and VATHOS studies. This expansion allows AstraZeneca to compete for a broader share of the respiratory market by positioning the three-in-one inhaler for patients with uncontrolled asthma.
A Shift in Pharma Marketing
The creative direction represents a departure from standard "lifestyle" pharmaceutical tropes. Because the asthma patient population typically skews younger than those suffering from COPD, AstraZeneca has pivoted its media spend. While previous COPD marketing often featured settings like RVs or cruise ships, this campaign leans heavily into social media to capture a more youthful audience.
According to Katie Pansegrau, AstraZeneca's senior director of marketing, the goal is to make scientific concepts feel "more light-hearted, more accessible and more educational," ensuring patients feel they understand their treatment. Brian Wood, senior vice president and group creative director at Edelman, noted that the team embraced being "bold" and "wonderfully weird" to increase the memorability of the medical message.
Industry Implications
By utilizing AI-generated imagery rather than traditional CGI or live animals, AstraZeneca is signaling a shift toward generative AI in highly regulated healthcare marketing. The move suggests that pharmaceutical companies are becoming more willing to use surrealism and humor to break through the noise of digital advertising, provided the core scientific claims remain accurate.
Industry observers will be watching to see if this "entertainment-first" approach leads to higher patient acquisition rates in the asthma sector compared to traditional clinical messaging. As AI tools become more integrated into agency workflows, the Breztri campaign may serve as a blueprint for how other biotech firms translate dense pharmacological data into viral, consumer-friendly content.